The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Class-Sparing Regimens for Initial Treatment of HIV-1 Infection
Open accessAbstract
BACKGROUND: The use of either efavirenz or lopinavir-ritonavir plus two nucleoside reverse-transcriptase inhibitors (NRTIs) is recommended for initial therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection, but which of the two regimens has greater efficacy is not known. The alternative regimen of lopinavir-ritonavir plus efavirenz may prevent toxic effects associated with NRTIs. METHODS: In an open-label study, we compared three regimens for initial therapy: efavirenz plus two NRTIs (efavirenz group), lopinavir-ritonavir plus two NRTIs (lopinavir-ritonavir group), and lopinavir-ritonavir plus efavirenz (NRTI-sparing group). We randomly assigned 757 patients with a median CD4 count of 191 cells per cubic millimeter and a median HIV-1 RNA level of 4.8 log10 copies per milliliter to the three groups. RESULTS: At a median follow-up of 112 weeks, the time to virologic failure was longer in the efavirenz group than in the lopinavir-ritonavir group (P=0.006) but was not significantly different in the NRTI-sparing group from the time in either of the other two groups. At week 96, the proportion of patients with fewer than 50 copies of plasma HIV-1 RNA per milliliter was 89% in the efavirenz group, 77% in the lopinavir-ritonavir group, and 83% in the NRTI-sparing group (P=0.003 for the comparison between the efavirenz group and the lopinavir-ritonavir group). The groups did not differ significantly in the time to discontinuation because of toxic effects. At virologic failure, antiretroviral resistance mutations were more frequent in the NRTI-sparing group than in the other two groups. CONCLUSIONS: Virologic failure was less likely in the efavirenz group than in the lopinavir-ritonavir group. The virologic efficacy of the NRTI-sparing regimen was similar to that of the efavirenz regimen but was more likely to be associated with drug resistance. (ClinicalTrials.gov number, NCT00050895 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UPDATE ON DRUG RESISTANCE MUTATIONS IN HIV-1
&NA; (2001) · Infectious Diseases in Clinical Practice · doi:10.1097/00019048-200106000-00020 · Cited by 1,660
Chesney, M. A., Ickovics, J. R., Chambers, D. B., Gifford, A. L., Neidig, J., Zwickl, B., Wu, A. W., & PATIENT CARE COMMITTEE & ADHERENCE (2000) · AIDS Care · doi:10.1080/09540120050042891 · Cited by 1,428
Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society–USA Panel
Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M. A., Carpenter, C. C. J., Fischl, M. A., Gazzard, B. G., et al. (2006) · JAMA · doi:10.1001/jama.296.7.827 · Cited by 1,033
Staszewski, S., Morales-Ramirez, J., Tashima, K. T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D. F., Farina, D., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412501 · Cited by 993
Treatment for Adult HIV Infection: 2004 Recommendations of the International AIDS Society-USA Panel
Yeni, P. G., Hammer, S. M., Hirsch, M. S., Saag, M. S., Schechter, M., Carpenter, C. C. J., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Jacobsen, D. M., et al. (2004) · JAMA · doi:10.1001/jama.292.2.251 · Cited by 737
Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection
Walmsley, S., Bernstein, B., King, M., Arribas, J., Beall, G., Ruane, P., Johnson, M., Johnson, D., Lalonde, R., Japour, A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012354 · Cited by 647
Carr, A., Miller, J., Law, M., & Cooper, D. A. (2000) · AIDS · doi:10.1097/00002030-200002180-00001 · Cited by 630
Gulick, R. M., Ribaudo, H. J., Shikuma, C. M., Lustgarten, S., Squires, K. E., Meyer, W. A., Acosta, E. P., Schackman, B. R., Pilcher, C. D., Murphy, R. L., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031772 · Cited by 522
Self-citationMallal, S. A., John, M., Moore, C. B., James, I. R., & McKinnon, E. J. (2000) · AIDS · doi:10.1097/00002030-200007070-00002 · Cited by 510
Update of the drug resistance mutations in HIV-1: Fall 2005.
Johnson, V. A., Brun‐Vézinet, F., Clotet, B., Conway, B., Kuritzkes, D. R., Pillay, D., Schapiro, J., Telenti, A., & Richman, D. D. (2005) · PubMed · Cited by 333
Murphy, R. L., Brun, S., Hicks, C., Eron, J. J., Gulick, R., King, M., White, A. C., Benson, C., Thompson, M., Kessler, H. A., et al. (2001) · AIDS · doi:10.1097/00002030-200101050-00002 · Cited by 238
Self-citationKempf, D. J., King, M. S., Bernstein, B., Cernohous, P., Bauer, E., Moseley, J., Gu, K., Hsu, A., Brun, S., & Sun, E. (2004) · The Journal of Infectious Diseases · doi:10.1086/380509 · Cited by 217
Dubé, M. P., Parker, R. A., Tebas, P., Grinspoon, S. K., Zackin, R. A., Robbins, G. K., Roubenoff, R., Shafer, R. W., Wininger, D. A., Meyer, W. A., et al. (2005) · AIDS · doi:10.1097/01.aids.0000183629.20041.bb · Cited by 189
MacArthur, R. D., Novak, R. M., Peng, G., Chen, L., Xiang, Y., Hullsiek, K. H., Kozal, M. J., van den Berg-Wolf, M., Henely, C., Schmetter, B., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69861-9 · Cited by 139
Hicks, C. B., King, M. S., Gulick, R. M., White, A. C., Eron, J. J., Kessler, H. A., Benson, C. A., King, K. R., Murphy, R. L., & Brun, S. C. (2004) · AIDS · doi:10.1097/00002030-200403260-00008 · Cited by 111
Self-citationAllavena, C., Ferré, V., Brunet-François, C., Delfraissy, J., Lafeuillade, A., Valantin, M., Bentata, M., Michelet, C., Poizot‐Martin, I., Dailly, É., et al. (2005) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000165914.42827.bb · Cited by 37
DiRienzo, A. G., & DeGruttola, V. G. (2003) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00321-5 · Cited by 17
Self-citation
Cited by
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Worm, S. W., Sabin, C., Weber, R., Reiss, P., El‐Sadr, W., Dabis, F., De Wit, S., Law, M., Monforte, A. D., Friis‐Møller, N., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/649897 · Cited by 648
HIV protease inhibitors: a review of molecular selectivity and toxicity
Wang, Y., Lv, Z., & Chu, Y. (2015) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s79956 · Cited by 450
Antiretroviral therapy and management of HIV infection
Volberding, P. A., & Deeks, S. G. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60676-9 · Cited by 449
Metadata
- Authors
- Riddler, S. A., Haubrich, R., DiRienzo, A. G., Peeples, L., Powderly, W. G., Klingman, K. L., Garren, K. W., George, T., Rooney, J. F., Brizz, B., Lalloo, U. G., Murphy, R. L., Swindells, S., Havlir, D., & Mellors, J. W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-15
- Volume
- 358
- Issue
- 20
- Pages
- 2095-2106
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2119433625
- Cited by
- 680
- References
- 17
- FWCI
- 59.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.